Increased Understanding of Stem Cell Behavior in Neurodegenerative and Neuromuscular Disorders by Use of Noninvasive Cell Imaging by Holvoet, Bryan et al.
Review Article
Increased Understanding of Stem Cell Behavior in
Neurodegenerative and Neuromuscular Disorders by
Use of Noninvasive Cell Imaging
Bryan Holvoet,1 Liesbeth De Waele,2 Mattia Quattrocelli,3 Olivier Gheysens,1
Maurillio Sampaolesi,3 Catherine M. Verfaillie,4 and Christophe M. Deroose1,5
1Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium
2Department of Development and Regeneration, Kulak Kortrijk, Department of Paediatric Neurology,
University Hospitals Leuven, 3000 Leuven, Belgium
3Translational Cardiomyology Lab, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium
4Stem Cell Institute Leuven, Department of Development and Regeneration, KU Leuven, 3000 Leuven, Belgium
5UZ Leuven, Division of Nuclear Medicine, Campus Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
Correspondence should be addressed to Christophe M. Deroose; christophe.deroose@uzleuven.be
Received 25 September 2015; Revised 7 January 2016; Accepted 11 January 2016
Academic Editor: Christian Dani
Copyright © 2016 Bryan Holvoet et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Numerous neurodegenerative and neuromuscular disorders are associated with cell-specific depletion in the human body. This
imbalance in tissue homeostasis is in healthy individuals repaired by the presence of endogenous stem cells that can replace the
lost cell type. However, in most disorders, a genetic origin or limited presence or exhaustion of stem cells impairs correct cell
replacement. During the last 30 years, methods to readily isolate and expand stem cells have been developed and this resulted in
a major change in the regenerative medicine field as it generates sufficient amount of cells for human transplantation applications.
Furthermore, stem cells have been shown to release cytokines with beneficial effects for several diseases. At present however, clinical
stem cell transplantations studies are struggling to demonstrate clinical efficacy despite promising preclinical results. Therefore, to
allow stem cell therapy to achieve its full potential, more insight in their in vivo behavior has to be achieved. Different methods
to noninvasively monitor these cells have been developed and are discussed. In some cases, stem cell monitoring even reached the
clinical setting. We anticipate that by further exploring these imaging possibilities and unraveling their in vivo behavior further
improvement in stem cell transplantations will be achieved.
1. Stem Cells
Stem cells are primitive cells that have 3major characteristics.
First, stem cells have a certain potency allowing them to dif-
ferentiate towards multiple cell types. Second, stem cells have
the ability to self-renewmeaning they can undergo numerous
cell cycles while maintaining their differentiation potency.
Third, stem cells can functionally reconstitute a tissue in vivo
[1]. These unique features make them attractive candidates
for the field of regenerative medicine.
In this review,we have focused on adult stem cells because
they have already been shown to be safe in clinical trials.
We will more specifically discuss neural stem cells (NSCs),
mesenchymal stem cells (MSCs), satellite cells (SCs), and
mesoangioblasts (MABs) since all of them have been eval-
uated for therapeutic potential in neurodegenerative and
neuromuscular disorders.
First it was thought that NSCs play an essential role
during the development of the central nervous system (CNS)
until it was terminally differentiated during adulthood [2]. In
the last 2 decades several studies discovered that NSCs are
still present inside the adult CNS [3].They have been demon-
strated to release beneficial cytokines in the regeneration and
repair of neural tissues but also to differentiate in vitro and in
vivo into diverse neuronal lineages and to formnetworks with
surrounding neuronal cells [4, 5].
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MSCs represent a very small fraction of bone marrow
(0.001%–0.01%) and were first isolated from bone marrow
by Friedenstein et al. in 1968 [6]. They have shown to
differentiate towards several cell types, including adipocytes,
chondrocytes, osteoblasts, and fibroblasts and more recently
Woodbury et al. achieved neuron-like differentiation of MSC
[7, 8]. Besides isolation from the bone marrow, MSCs have
been isolated from almost every tissue and can be readily
expanded in vitro [9]. Furthermore, MSCs lack immuno-
genicity and even reduce inflammation and suppress T-
cell proliferation [10]. MSCs exert the majority of their
effects via their immunomodulatory, neurotropic, and repair-
promoting properties. Their effect has been assessed in
numerous diseasemodels, including neurologic diseases, and
has even reached translation towards clinical trials [11–13].
SCs are located in the periphery of the skeletal myofibers.
In mature muscles SCs remain quiescent but following
muscle injury they regain mitotic activity and are able to
repair the incurred muscle damage [14]. These cells and their
derivatives are therefore highly explored for treating several
muscle disorders; for a detailed review see Berardi et al. [15].
MABs are vessel-associated stem cells, which were ini-
tially isolated from the fetal aorta but are now readily
isolated from postnatal vessels of skeletal muscle or heart
[16]. They are capable of differentiating towards cell types of
the mesodermal lineages, namely, adipocytes, chondrocytes,
osteoblasts, and fibroblasts like MSCs [17]. In contrast with
MSCs however, MABs differentiate with high efficiency
towards myofibers both in vitro and in vivo following trans-
plantation in dystrophic animals [18].
2. Stem Cell Therapies in
Neurodegenerative and Neuromuscular
Disorders and Acute Injuries
Neurodegenerative and neuromuscular disorders are the
consequence of progressive and irreversible cell loss in the
human body. Neurodegenerative disorders, like Parkinson’s
disease (PD) and Huntington’s disease (HD), are caused by
progressive loss of neurons and mainly impair cognitive
function. Neuromuscular disorders can be caused either by
motor neuron loss (amyotrophic lateral sclerosis; ALS) or
by loss of the actual muscle cells, with Duchenne muscular
dystrophy (DMD) as most prevalent example. Furthermore,
acute neuronal injuries (spinal cord injury (SCI) and trau-
matic brain injury (TBI)) also can result in permanent cell
loss due to the limited regenerative potential of NSCs. In
all these disorders the endogenous stem cells are exhausted
and cannot compensate this progressive cell loss. To date no
curative treatment has been developed for these disorders.
The fact that stem cells compensate normal tissue
turnover, release beneficial paracrine molecules, and are
readily isolated and expanded in vitromakes them attractive
tools for regenerative medicine [19]. We will briefly discuss
the different stem cell therapies performed in several neu-
rodegenerative and neuromuscular disorders.
2.1. Stem Cell Therapy in Neurodegenerative Disorders
2.1.1. Huntington Disease. Huntington’s disease (HD) is
caused by a repeated trinucleotide (CAG) within the Hunt-
ingtin gene and results in choreiformmovements, limb inco-
ordination, and impaired motor function. These choreiform
movements are the consequence of death of the medium
spiny neurons (MSN) in the caudate, putamen, and globus
pallidus [20]. Several groups demonstrated improved motor
function after NSCs transplantation [21–25]. In one HD
patient who died from cardiovascular disease 18 months after
transplantation of neuroblasts, postmortemhistological anal-
ysis demonstrated surviving transplanted cells with striatal-
like morphology without apparent immunological rejection
[26].
2.1.2. Parkinson’s Disease. Parkinson’s disease (PD) is a neu-
rodegenerative disorders caused by the selective death of
dopamine-producing neurons in the substantia nigra. In the
early stage of the disease the symptoms are mainly move-
ment-related including tremor, rigidity, and bradykinesia
[27]. In the later stage, cognitive impairment is also observed.
At the end of the 20th century, several open-label non-
controlled clinical trials were performed using human fetal
dopaminergic neurons to replace the loss of dopaminergic
neurons in PD patients. These studies demonstrated a mild
recovery of motor function and higher presynaptic dopamin-
ergic function detected with positron emission tomography
(PET) showing higher uptake of 18F-fluorodopa [28, 29].
However, these improvements were not seen in all patients,
and two large randomized double-blind clinical trials with
neural grafts showed no clinical efficacy [29–31]. These
contrasting results have resulted in a large debate if neural
transplants could be effective in treating PD patients. One
part of the field believes that the beneficial effects seen in the
first studies are the consequence of placebo and nonblinded
observers, while the other group believes the design of the
randomized trials was not optimal [32].
Besides NSCs also MSCs have been evaluated for therapy
in PD.The advantage is that they aremore readily isolated and
expanded in vitro than NSCs. Furthermore, differentiation
potential towards neuron-like cells and excretion of cytokines
and neurotrophic factors has been documented [8, 13].
Starting in 2005, the potential of MSCs in PD was evaluated
and protective effects of MSCs on dopaminergic neurons
were described [33–35]. The observed beneficial effects of
the neurotrophic factor glial cell line-derived neurotrophic
factor (GDNF) resulted in studies in which these factors were
overexpressed in transplantedMSC [36–38]. Transplantation
of these genetically engineered MSCs resulted in functional
improvement in PD animal models. Some studies also
demonstrated neuronal differentiation of NSCs with increase
in the proportion of tyrosine hydroxylase- (TH-) posi-
tive and dopamine-producing cells associated with clinical
improvements [39–43]. These beneficial preclinical effects
have resulted in an open-label study to determine the safety
of unilateral transplantation of autologousMSCs in seven PD
patients [44]. Only a marginal clinical improvement in three
out of the seven patients was observed.
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2.2. Stem Cell Therapy in Neuromuscular Disorders
2.2.1. Amyotrophic Lateral Sclerosis. Amyotrophic lateral
sclerosis (ALS), also known as Lou Gehrig’s diseases, is a
severe and very rapidly progressive neurodegenerative disor-
der characterized by degeneration ofmotor neurons followed
by loss of neuromuscular interaction resulting in muscle
atrophy with the associated progressive muscle weakness,
dysphagia, spasticity, and ultimately death.
MSCs transplantation following different transplantation
routes in rodent ALS animal models resulted in a significant
delay in ALS disease onset, amelioration of the pathophysi-
ology, and increased survival rate [45–50]. These beneficial
effects have been attributed to the neuroprotective effects of
MSC, reduced inflammation, and some transdifferentiation
towards healthy astrocytes [45–47]. The observed preclinical
improvement has led to several phase I studies demonstrating
the safety and feasibility of MSC treatment in ALS patients
[51–53]. However, the patient cohorts were too small to
evaluate efficacy.
2.2.2. Duchenne Muscular Dystrophy. Duchenne muscular
dystrophy (DMD) is a severe progressive muscle disorder
caused by mutations in the dystrophin gene located on
the X-chromosome. The associated muscle damage activates
resident endogenous primary muscle stem cells, namely, SCs
[54, 55]. However, endogenous stem cells also contain this
mutation and have limited self-renewal capacity. Therefore,
an inefficient muscle repair process occurs with associated
fatty acid depositions and muscle fibrosis. Despite the inef-
ficient regenerative process, the discovery of increased SC
proliferation forms the basis of current stem cell therapies for
DMD. At present, researchers have found beneficial effects
after intramuscular injection of different types of dystrophin
expressing myogenic progenitor cells (myoblasts, SC) [56–
60]. These beneficial effects have led to a clinical trial of
autologous transplantation of CD133+ cells, human muscle-
derived stem cells with myogenic potential, in 8 boys with
DMD [61]. As with previous stem cell transplantations, no
adverse events occurred. However, no functional improve-
ment was observed. The absence of functional improvement
is caused by insufficientmigration of themyoblasts, immuno-
logical clearance, and death ofmyoblasts after transplantation
[62–64].
The disadvantage of using myogenic progenitor cells is
the inability to migrate over a long distance and through the
vascular endothelial wall. This prevents systemic administra-
tion of these cells and hampers their clinical applicability.
Therefore, in recent years MABs have been studied to treat
dystrophic muscles. The advantage of MABs is the ability to
pass the endothelial wall of the vasculature and different stud-
ies have demonstrated regenerating muscle architecture with
functionality after intra-arterial injection both in dystrophic
alpha sarcoglycan- (Scga-) null mice and in golden-retriever
muscular dystrophy (GRMD) dogs [65, 66].These promising
preclinical studies have resulted in a phase I/II clinical trial
in 5 DMD patients [67]. The infusion of the cells was rela-
tively safe; one patient however developed a thalamic stroke
without clinical consequences. No functional improvement
could however be observed and very low level of donor DNA
was retrieved in muscle biopsies of the patients.
2.3. Stem Cell Therapy in Acute Injuries
2.3.1. Traumatic Brain Injury. Traumatic brain injury (TBI)
is becoming increasingly important as indicated by its rapid
increase in incidence in different countries [68]. Further-
more, TBI is a well-established risk factor for different
neurodegenerative diseases [69]. NSCs improved metabolic
recovery and neurological motor function in a TBI rat model
[70]. MSCs have shown to elicit neuroprotective and regen-
erative effects after administration in TBI animal models [71,
72]. Contrasting studies which showed no improvement have
also been reported [73].
2.3.2. Spinal Cord Injury. Spinal cord injury (SCI) occurs
after traumatic damage to the spinal cord which is associated
with severe consequences andmight even result in death [74].
The transplantation of NSCs in SCI models resulted in astro-
cytic and neuronal differentiation and improved remyeli-
nation, motor function, and sensory perceptions [75–83].
Another study also found glial and neuronal differentiation;
however no functional improvement could be found [84].
MSCs have demonstrated to have beneficial effects in
models of SCI and their effect is mediated through reduced
inflammation, improved angiogenesis, suppression of neu-
roinhibitory molecules, reduced demyelination, and induc-
tion of remyelination [85–98].The paracrine factors involved
in these positive effects were brain-derived neurotrophic
factor (BDNF), GDNF, nerve growth factor (NGF), leukemia
inhibitory factor (LIF), and insulin-like growth factor-1 (IGF-
1) [91, 99, 100]. MSC treatment in patients with SCI was
shown to be safe, with some modest improvement in clinical
scores [101–104].
3. Stem Cell Imaging
Despite the progress into clinical trials, limited information is
available on the distribution, migration, and survival of these
cells in living organisms over time [105]. At present, histology
is the golden standard in preclinical cell monitoring. How-
ever, this requires the sacrifice of numerous animals and can
only be obtained in a very limited manner in clinical trials,
hampering clinical translation. Furthermore, it provides no
longitudinal or whole body monitoring. This results in a
shortage of information on stem cell behavior in vivo. There-
fore, noninvasive cell monitoring methods have been devel-
oped [106–108].This provides direct visualization of stem cell
delivery together with an indication of the location of the
transplanted cells and their survival over time.
Stem cell imaging approaches can be divided into direct
and indirect cell labeling. Direct cell labeling is the most
frequently used method and consists of labeling cells in vitro
with reporter probes, including fluorophores, radiotracers,
or paramagnetic nanoparticles (NP), by incubation before
transplantation (Figure 1) [106, 109]. These reporter probes
can either bind to specific epitopes on the cell membrane,
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Figure 1: Schematic overview of the processes involved in direct cell labeling. Cells are first labeled with contrast agents in vitro through
incubation, harvested, and injected into a subject (adapted from [106]).
like a copper-64-labeled antibody or zirconium-89-desferri-
oxamine-NCS (89Zr-DBN) [110, 111], or be taken up by passive
diffusion or transporters, like indium-111- and 89Zr-oxine
or 2-[18F]-fluoro-2-deoxyglucose (18F-FDG) [112, 113]. After
incubation, the cells are injected in vivo for cell monitor-
ing by optical imaging, single photon emission computed
tomography (SPECT), positron emission tomography (PET),
or magnetic resonance imaging (MRI).
The direct cell labeling procedure is straightforward and
this is the major advantage of direct labeling. However, for
radionuclide imaging this labeling strategy is limited to short-
term cell visualization based on the half-lives of the tracers
(𝑡
1/2
fluorine-18 = 110min; 𝑡
1/2
indium-111 = 67.32 h; 𝑡
1/2
zirconium-89 = 78.41 h) [118, 119]. Also, the proliferation of
directly labeled cells results in the dilution of the reporter
probe preventing the visualization of daughter cells and
compromising the correlation of the observed imaging signal
with cell amount. Another disadvantage, mainly for NP, is
the persistence of the probe after cell death, which results in
reporter probe transfer towards adjacent phagocytic cells like
macrophages andmicroglia.This prevents correct correlation
between the obtained image signal and cell viability [120, 121].
Indirect cell labeling consists of cellular modification by
inserting an exogenous reporter gene into cells (Figure 2).
For stem cell monitoring, the reporter gene is inserted into
the stem cell before transplantation [106]. Reporter genes are
genes that encode proteins that can be detected by nonin-
vasive imaging, either directly or because they bind a signal
generating ligand.
Nuclear imaging reporter genes are transporters (e.g.,
sodium iodide symporter (NIS)), receptors (e.g., dopamine
receptor type 2 (D
2
R) or somatostatin receptor type 2), or
enzymes (e.g., herpes simplex virus type 1 thymidine kinase
(HSV1-tk)) for which radiolabeled ligands have been devel-
oped. After transfer of the reporter gene and its transcription
and translation into a protein, the cells are able to bind,
accumulate, or convert an exogenously given reporter probe.
This results in specific uptake of the reporter probe in reporter
gene-expressing cells and allows long-term longitudinal non-
invasive visualization of cells in vivo. Indeed, after decay of the
reporter probe (e.g., after 5 half-lives) a novel administration
can be performed and the distribution of the reporter probe
will reflect reporter gene expression at that time point.
Furthermore, the accumulation of the reporter probe is pro-
portional to the total gene expression and thus to the total cell
amount.
Because only viable cells translate the reporter gene into
a protein, a distinction between viable and nonviable cells
can be made [107]. The disadvantage of this technique is the
insertion of genomic material into a cell which might disrupt
normal cell physiology [122, 123]. However, with novel site-
specific gene editing approaches the reporter genes can
become integrated in a safe harbor locus [124, 125].
4. Imaging Studies Performed with
Stem Cells in Healthy Animals
4.1. Direct Cell Labeling. One of the most frequently used
direct cell labeling approaches is via the use of superparam-
agnetic iron oxide (SPIO) NP which generate a hypointense
contrast onMRI. Several aspects are important when design-
ing SPIOs for cell labeling. The SPIOs need to be readily
taken up by the cell and have a high T2 relaxivity to generate
contrast, long-term retention in the cell and biocompatibility
with the cell and host (for detailed review see Li et al. [126]).
Successful labeling of NSCs [114, 127, 128], MSCs [129–133],
SCs [129, 134, 135], and MABs [136] with SPIO NP has
been demonstrated by different groups and shown to be
without any consequence on viability, differentiation capacity,
or biological characteristics. Cromer Berman et al. however
observed an impairment ofNSCmotility andmigration, both
in vitro as in vivo [137].
Cicchetti et al. were able to demonstrate via MRI
rostral migratory stream (RMS) migration of transplanted
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Figure 2: Schematic overview of the steps involved in indirect cell labeling. First, imaging reporter gene expression is induced in vitro in
host cells. Reporter gene expressing cells are harvested and injected into a subject. In a next step, the respective radiotracer is injected and
imaging can be performed to determine the localization of the cells. Repetitive injection of the radiotracer allows for repetitive imaging and
thus long-term visualization of the engrafted cells [106].
SPIO-labeled NSCs (Figure 3) [114]. This was associated with
enhanced expression of D
2
R and dopamine transporter as
indicated by increased 11C-raclopride and 11C-CFT bind-
ing, respectively. Afterwards immunohistochemistry demon-
strated that this was the consequence of host-derived changes
because the transplanted cells were still at an early stage of
development.
The disadvantage of SPIO-based cell labeling is the
possibility of aspecific uptake of the NP by macrophages and
microglia. Berman et al. combined SPIO-labeling with indi-
rect cell labeling via NSCs expressing firefly luciferase (Fluc)
to monitor cell survival in immunocompetent and immun-
odeficient animals [138]. Only in immunodeficient animals
long-term cell monitoring via bioluminescence imaging
(BLI) was achieved. In contrast, hypointense SPIO signals
on MRI were persistent both in immunocompetent and in
immunodeficient animals. Histology demonstrated that even
in the immunodeficient animals no colocalization of the
SPIOs with the NSCs occurred and that the particles were
taken up bymicroglia (the resident immune cells of theCNS).
Therefore, caution needs to be taken into account for the
interpretation of SPIO-based imaging results.
Other disadvantages of SPIO-based cell monitoring are
the low specificity due to other organs with hypointense sig-
nal and the complicated in vivo quantification of the signal
loss.
Therefore, recently an alternative MRI-based method has
been evaluated, namely, 19FMRI, which detects the stable iso-
tope fluorine-19. In contrast to SPIO-based cell monitoring,
19F MRI is able to image implanted cells with high specificity
due to the lack of detectable fluorine signal in biological tissue
[139, 140]. Furthermore, quantification of the implanted cells
is possible since the 19FMRI signal intensity is linearly related
to the number of 19F-labeled cells. Successful labeling ofNSCs
[140] and MSCs [141] with 19F NP was achieved without
altering cell characteristics. No leakage of the NP towards
surroundingmacrophages was observed in 19F-labeledNSCs.
However, the 19F contrast used for labeling of MSCs was
localized in macrophages instead of the grafted cells. There-
fore, also via this approach the observed imaging results
might not correspond with the injected cell population.
Radionuclide imaging techniques are highly quantitative
in nature and therefore several groups have directly labeled
NSCs and MSCs with either 18F-FDG [142], 99mTc-HMPAO
[143–146], or 111In-oxine [147–149]. After labeling with
radionuclides no differences in viability or differentiation
capacity were shown; no ultrastructural changes were shown
either [111, 142–144, 147–149]. 18F-FDG did also not induce
metabolic changes while 111In-oxine reduced metabolic
activity andmotility of the cells [148]. A reduced proliferation
rate was also seen in 99mTc-labeledNSCs, probably because of
DNA damage induced by Auger electrons [146].
All previous radionuclides have a relatively short half-life
(𝑡
1/2
18F = 110min; 𝑡
1/2
99mTc = 6.03 h; 𝑡
1/2
111In = 67.32 h)
and are therefore restricted to short-term cell monitoring
with 5 half-lives as upper limit. Furthermore, relative high
efflux rates are observed with some of these radionuclide
labeling approaches [142, 150]. Bansal et al. developed a 89Zr-
DBN labeling agent which is capable of covalently binding
to the cell surface and allows cell monitoring for 2 to 3
weeks because of the long half-life (78.41 h) [111]. Seven days
after intravenous injection of 89Zr-labeled MSCs in healthy
athymic mice, cells could mainly be detected in the lungs
(50 ± 27%). The remainder was found in the liver (27 ± 19%)
and the bones (16 ± 5%). In an acute myocardial ischemia
model, 89Zr-labeled MSCs were injected in the ischemic area
of the heart. Seven days after delivery, 20 ± 7% of the cells
were maintained in the heart while the other fraction was
distributed to the lungs (40±16%), bone (29±11%), and liver
(7 ± 5%).
Both MRI and PET have a temporal resolution in the
order of several seconds to minutes, which precludes them







Figure 3: Longitudinal MRI studies of transplanted SVZ cells. T2-weighted MRI studies of transplanted SVZ cells 2 h after transplantation
into the striatum (a) and 21 days later (b). Images were acquiredwith a 9.4 Tmachine.The needle track and cell transplant have been arbitrarily
delineated by a dotted blue line. The schematic atlas drawings have been overlaid onto MRI images to facilitate anatomical localization of the
graft site (see methods for overlay procedure). (c) Prussian blue staining of the rat striatum depicts distribution of transplanted, iron oxide-
labeled SVZ cells one month after transplantation. Iron deposits stain blue with potassium ferrocyanide. Cells are also counterstained with
pararosaniline allowing the cytoplasm to appear as light pink also depicted in cells in vitro (see inset (c)). Further MRI of SVZ cells into the
RMS confirmed correct positioning of the graft immediately after the transplantation procedures (d) and normal localization and growth
14 days after transplantation (e). (f) A sagittal T2-weighted MR image shows the migration of SPIO-labeled SVZ cells towards the olfactory
bulb 7 days after transplantation. STR, striatum; CC, corpus callosum; LO, lateral orbital cortex; VLO, ventrolateral orbital cortex; MO/VO,
medial orbital cortex/ventral orbital cortex [114].
from being used during the cellular implantation procedure.
Photoacoustic imaging (PAI) could however be used because
of its high temporal resolution [151]. To allow monitoring
of MSCs with PAI, cells were labeled with silica-coated gold
nanorods. After intramuscular transplantation, successful
monitoring at high temporal resolution (0.2 s) could be
achieved with PAI until day 4. The lowest cell amount to be
monitored was 1.0 × 105 cells.
4.2. Indirect Cell Labeling. All the labeling approaches men-
tioned above are limited to short-term cell monitoring (hours
to weeks) or might generate aspecific signals. As an alter-
native, reporter gene-based strategies have been developed.
Not only does it allow long-term noninvasive imaging of
stem cells, it also makes a distinction between viable and
nonviable cells. The most widely used imaging reporter gene
is Fluc which catalyzes the oxidation from D-luciferin to
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Figure 4: In vivo long-term follow-up of stem cell migration with bioluminescence imaging (BLI). (a) At day 7 after injection there was a
detectable BLI signal only at the site of injection (SVZ). At 15 and 30weeks after injection an additional focus was detected at theOBprojection
site, as well as the original focus at the SVZ. A representative mouse is shown. (b) The graph shows the quantification of the in vivo OB BLI
signal from all the animals followed up for 30 weeks (𝑛 = 14). The OB photon flux at weeks 15 and 30 was significantly higher than that on
day 7 (𝑝 = .002 and .045). OB, olfactory bulb; p, photons; s, second; sr, steradian; SVZ, subventricular zone [115].
oxyluciferin with the release of visible light (principle of
BLI) in the presence of oxygen, magnesium, and adenosine
triphosphate.
Endogenous cells of the subventricular zone have been
labeled with enhanced green fluorescent protein (eGFP) and
Fluc via a lentiviral vector. Afterwards the migration of NSCs
towards the olfactory bulb (OB) via the RMS could clearly be
observed via BLI (Figure 4) [115]. A strong linear correlation
between the in vivo OB photon flux and number of eGFP-
positive cells on histology was shown.This allowed us to eval-
uate the effect of BDNF of neurogenesis of endogenous stem
cells. Short-term stimulation with BDNF (1 month or less)
demonstrated increased neurogenesis; in contrast however
long-term overexpression impaired migration and differen-
tiation of NSCs as indicated via BLI [115].
Incorporation of Fluc in NSCs [138], MSCs [152, 153], and
SCs [154] has been successfully performed for cellmonitoring
with BLI. This noninvasive read-out of cell survival was used
by Liang et al. to demonstrate that human NSCs expressing
Fluc had a significant increase in cell survival when coinjected
with helper cells expressing basic fibroblast growth factor
(bFGF) in the striatum [155]. Stem cell therapy can also be
combined with gene therapy; to visualize both cell survival
and therapeutic gene expression Gheysens et al. transduced
myoblasts with Fluc and HSV-tk to monitor cell survival and
transfected the cells with Renilla luciferase (Rluc) and the
therapeutic gene (hypoxia-inducible factor-1𝛼 fused to two
repeats of VP16; HIF-1𝛼-VP2) [154]. In vitro, a clear linear
correlation was found between HIF-1𝛼-VP2 and Rluc activ-
ity. Furthermore, they demonstrated that the recombinant
hybrid HIF-1𝛼-VP2 protein could effectively induce down-
stream angiogenic gene expression, indicated by the amount
of vascular endothelial growth factor (VEGF) and placental
growth factor (PIGF) in the supernatant of the cells. After
intramuscular injection of myoblasts expressing Fluc and
myoblasts expressing Fluc combined with Rluc and HIF-1𝛼-
VP2 (left and right leg, resp.) robust Fluc-mediated signal
was detected in both legs immediately after cell implantation,
whereas RLuc signal was only observed in the right leg.
Therefore, they were able to monitor transplanted cell sur-
vival and therapeutic transgene expression, which is crucial
for evaluating combined cell and gene therapy.
Although BLI is a valuable and widely used tool for pre-
clinical cell monitoring, it can never be translated towards a
clinical setting.Therefore, different PET and/or SPECT [156–
163] and MRI [163–167] reporter genes have been developed.
Endogenous neuronal cells have been labeled with the
MRI reporter gene ferritin. Ferritin is capable of taking
up iron and generates a hypointense (lack of) signal on
MRI. Stable transduction of the cells in the striatum was
feasible, and when no inflammation was present clear MRI
signals could be observed [166]. However, low sensitivity was
observed if there was ongoing inflammation because ferritin
is highly expressed on reactivemicroglia [168].VandeVelde et
al. evaluated the feasibility to monitor endogenous migration
of cells in the SVZ with ferritin as reporter gene [167]. Clear
hypointense regions on MRI were present in the transduced
area; however monitoring the RMS towards the OB via in
vivo MRI was not feasible because of low sensitivity. High
resolution ex vivoMRIwas capable of quantitatively detecting
hypointense regions in the OB; but based on visual assess-
ment this was not feasible. The divalent metal transporter 1
(DMT1) is a reporter gene that can be used for both MRI
and PET [163].Monitoring of humanNSCs expressingDMT1
after injection in the striatum was feasible with MRI after
manganese injection; 52Mn-based PET/CT was unable to
visualize the graft although ex vivo results demonstrated low
levels of brain uptake.
Also radionuclide reporter genes, namely, the D
2
R [160]
and the human NIS [161, 162], were used for labeling of
exogenous MSCs. Since binding of the ligand on wild-type
D
2
R activates a signaling pathway, a mutant variant, the so-
called D
2
RB80A, was developed with similar in vitro and in
vivo binding activity [160]. No long-term cell monitoring was
achieved withMSCs transduced with a baculovirus encoding
hNIS; however this was the consequence of transient reporter
gene expression via the baculovirus approach [161, 162].
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To benefit from the different imaging approaches reporter
genes were also combined to provide a better understanding
of the localization, survival, distribution, and differentiation
processes of stem cells in vivo. We combined Fluc with hNIS
in a lentiviral construct and this allowed us to monitor MSCs
via BLI, Cherenkov luminescence imaging, and PET [169].
Pei et al. combined Fluc with another radionuclide reporter
gene (HSV-tk) and successfully monitored the cells with BLI
and PET [170].
In the aforementioned studies only information on the
location of the cells is provided. To visualize the true differen-
tiation capacity of the cells noninvasively Hwang et al. devel-
oped a dual reporter gene system, expressing both Fluc and
NIS under control of the neuron-specific enolase (NSE) pro-
moter [171]. During neuronal differentiation of transfected
F11 cells, a cell line derived from dorsal-root-ganglion neu-
rons, a 4-fold increase in luciferase and NIS expression was
observed. In vivo, the differentiation of F11 cells towards neu-
rons could only be visualized with BLI but not with SPECT
[171]. In a different study, the impact of neuronal activator
neurogenin 1 (Ngn1) on neuronal differentiation was assessed
in F11 cells expressing Fluc under a neuronal promoter [172].
After subcutaneous and striatal injections an increase in
luciferase activity was observed in F11 cells cotransfected with
Ngn1 compared to sham transfected F11 cells. These studies
implicate the strength of imaging reporter genes to visualize
differentiation of cells in vivo.
5. Imaging Studies Performed with
Stem Cells in Disease Models and Patients
5.1. Huntington Disease. A single cell monitoring study has
been performed to visualize stem cells in HD animal models.
NSCs expressing Fluc were injected in the brain and clear
RMS migration of the NSCs towards the OB was observed
via BLI (Figure 5) [116]. These results are in agreement with
the labeling of endogenous stem cells and indicate that trans-
planted exogenous cells are able to follow similar migration
routes [115]. To also assess the effect of GDNF, NSCs were
also transduced to overexpress GDNF. A Huntington disease
mouse model was generated in which the lesion site had
a reduction of 86% in striatal neurons compared to the
nonlesion site.WhenFluc expressingNSCswere transplanted
higher cell proliferation was seen in the lesion site compared
to the nonlesioned striata; however no recovery in neuronal
death was observed when Fluc expressing NSCs were trans-
planted. In contrast mice receiving Fluc and GDNF express-
ing NSCs at the lesion site had mild reduction in neuronal
death, which demonstrated the neuronal protective effects
of GDNF. This was further confirmed via behavioral testing,
where a reduction in asymmetric behavior was observed
in HD mouse model after treatment with NSCs expressing
GDNF.
5.2. Parkinson’s Disease. To generate more insight in MSC-
mediated therapy in PD, Guo et al. labeledMSCs with SPIOs.
Different amounts of SPIO-labeled cells were injected in the
right striatum of a 6-hydroxydopamine (6-OHDA) PD rat
model, which is a widely used model to mimic PD. This
resulted in clear dose-dependent hypointense signal at the
site of injection for 12 weeks [173]. Extensive migration of
transplanted cells towards the lesion site was only detectable
on histology. In contrast to the MRI images, only a few
iron-labeled MSCs were found in the striatum where the
hypointense signal was located on the MRI scans. Fur-
thermore, they observed an increase in dopaminergic glial
fibrillary acidic protein (GFAP), NSE, and nestin following
transplantation, which suggest that either the transplantation
enhanced the differentiation of resident stem cells or some of
the transplanted cells had differentiated.
Im et al. demonstrated via BLI that there is no difference
in NSCs survival when transplanted in the right striatum
of 6-OHDA mouse model or healthy mice [174]. In both
animal groups cells were lost 10 days after injection. Behav-
ioral testing demonstrated significant increase in asymmetric
behavior in the 6-OHDA mouse model. This was further
confirmed by reduced binding of 18FN-(3-fluoropropyl)-
2󸀠-carbomethoxy-3󸀠-(4-iodophenyl)nortropane (18FP-CIT),
which binds the dopamine transporter, in the right striatum
of the 6-OHDA mouse model. At 1 week after injection
no difference in cell- and sham-injected groups could be
observed. At 4 weeks after injection however, a significant
reduction in asymmetrical behaviorwas shown in cell-treated
animals. On PET no improvement in striatal binding poten-
tial (BP) ratio after cell transplantation was observed in the
6-OHDA mouse model group. Histology demonstrated that
themajority of the transplanted cells died in the early phase of
transplantation with only a small fraction of cells capable of
surviving. However, this was below the detection limit of BLI.
5.3. Amyotrophic Lateral Sclerosis. To increase the under-
standing of potential mechanism of MSC therapy in ALS,
Canzi et al. labeled skeletal-derived MSCs with SPIOs and
injected them intracerebroventricularly in a murine model
of spontaneous motor neuron degeneration (the Wobbler
mouse) [175]. MRI showed hypointense signals throughout
the ventricular system one day after cell transplantation and
this signal decreased but remained detectable until 14 weeks
after transplantation. Based on immunostaining only modest
human MSCs integration in the brain parenchyma could
be demonstrated. To validate the clinical improvement, cell
transplantations were performed without cell labeling. This
however prevents the correlation of functional effects with
the imaging results. Furthermore, no assessment of the label-
ing procedure on the beneficial effects of the cells could be
made. The nonlabeled cells improved the forepaw atrophy
and grip strength.Thismight be caused by amodest improve-
ment in the percentage of active neuromuscular junctions
and a mild attenuation of microglial activation. The authors
attributed the effects to the release of the anti-inflammatory
cytokines interleukin-10 (IL-10) and IL-13 by the transplanted
MSCs. These cytokines were however not able to reduce
motor neuron death in these Wobbler mice as indicated by
histology.
5.4. Duchenne Muscular Dystrophy. To evaluate the in
vivo behavior of myoblast progenitors overexpressing mini













Figure 5: Tracking of NSC migration by in vivo optical neuroimaging. (a) Diagram showing the rostral migratory stream of endogenous
NSCs, from the subventricular zone to the olfactory bulb. (b) Optical neuroimage of c17.2/Luc-NSCs transplanted in the mouse rostral
migratory stream, acquired 1 week after grafting. (c) Bioluminescent spot (arrow) detected over the olfactory bulb of the samemouse 6 weeks
after grafting. The arrowheads indicate the grafting sites. (d) Histological analysis showing eGFP-positive c17.2/Luc-NSCs in the olfactory
bulb. Counterstaining with DAPI (blue) shows the presence of eGFP-expressing cells in the glomerular and granular cell layers, the natural
migration target for NSCs of the subventricular zone (𝑛 = 3) [116].
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dystrophin Cahill et al. labeled them with SPIOs [176]. SPIO-
labeled cells were injected in the posterior leg musculature
and a hypointense signal could be observed on MRI at all-
time points (end point day 14). Engrafted cells were detected
by histology and dystrophin expressing fibers with iron con-
tent were found. A small number of macrophages, which are
frequently present in regenerating fibers, also contained iron.
To evaluate the transfer of SPIOs after cell death towards other
cells human SPIO-labeled MSCs were injected into immune
competent mice. A slow decrease in SPIO-induced contrast
over time was observed. These results indicate that it may
require at least 2months following an intramuscular injection
before large amounts of residual SPIOs are removed. Because
all the striated muscles in the human body are affected by
DMD, systemic cell administration strategies have been eval-
uated. After intra-arterial injection SPIO-labeled myoblast
progenitors were visualized in the vasculature of the muscle
via MRI [176]. Histology confirmed the presence of labeled
cells within the arteries and capillaries but not inside the
muscle fibers. In contrast to intramuscular injection, intra-
arterial injection resulted in rapid clearance of the cells 3 days
after transplantation.
In contrast to myoblast progenitors, MABs are capable
of crossing the vessel endothelial wall. Therefore, also MABs
were labeled with SPIOs [136]. If these cells were injected
in the gastrocnemius of mdx mice, which is a DMD animal
model, cells were clearly visible 24 h following delivery and
remained visible in the following 2 weeks. SPIO-labeled
MABs were also injected in the left ventricular wall of the
heart and remained visible until 6 months after injection.
Histology demonstrated that all detectable iron-labeled cells
were however proinflammatory macrophages which clearly
confound the observed imaging results. Some MABs may
have survived since low levels of dystrophin were detectable
in cell-injected animals, although there is always the risk of
revertant fibers by spontaneous mutation restoring the non-
sense mutation in the dystrophin gene. Since DMD affects
striated muscles throughout the body, systemic delivery of
stem will be necessary. Therefore, SPIO-labeled MABs were
injected in the left ventricle of mdx mice. After 5 days,
cells were not detectable in filter organs or in muscle tissue
via MRI. Postmortem analysis however indicated that iron-
labeled cells had localized to dystrophic skeletal muscles and
vessels in cardiac muscle.
To understandmore aboutMABs survival and the impact
on immune suppressants on cell survival, we transduced
MABs with Fluc and hNIS [177]. MABs expressing Fluc and
hNIS were intra-arterially injected in Sgca−/− mice, which
is a dystrophic animal model, and visualized via both BLI
and PET. Based on noninvasive imaging data we were able
to demonstrate that costimulation adhesion blockade therapy
was superior to cyclosporine A in reducing cell rejection. T-
cell analysis showed us that costimulation adhesion blockade
therapy was capable of reducing the number of cytotoxic
T-cells and upregulating the regulatory T-cells. Although
costimulation adhesion blockade therapy was a superior
immune suppressant it was not able to achieve long-term cell
survival with day 21 after injection as latest time point to
visualize the cells. In theMAB-treated animals with costimu-
lation adhesion blockade as immune suppression a transient
improvement in running distancewas observed togetherwith
mild reexpression of alpha sarcoglycan.
5.5. Traumatic Brain Injury. To improve the understanding
of MSC-based therapy in TBI, several noninvasive MSC
tracking studies have been performed. SPIO-labeled MSCs
could be visualized after intracranial injection via MRI in
brain lesion models [132, 178]. When a lesion was present
MSCsmigrated preferentially towards the lesion site. Jackson
et al. were able to visualize this migration by MRI while
Delcroix et al. were only capable of showing this via histology
[132, 178]. To avoid the invasive intracranial administration
procedure, systemic administration routes have been evalu-
ated either with directly labeled MSCs using SPIOs for MRI
[132, 133] or with radionuclides (99mTc-HMPAO and 111In-
oxine/tropolone) [144, 149]. Again, migration towards the
lesion site was observed and could be visualized via MRI and
SPECT [132, 133, 149]. Park et al. were unable to visualize
99mTc-HMPAO-labeled MSCs in the brain; however ex vivo
uptake showed increased uptake in the lesion site compared
to the contralateral site [144]. Huang et al. further demon-
strated that specific SPIO design clearly upregulated CXCR4
expression [133]. The overexpression of CXCR4 resulted in
increased cell migration both in vitro and in vivo in response
to SDF-1𝛼, the ligand ofCXCR4,which is highly secreted after
TBI. MSC-treated mice showed signs of decreased contusion
volume and less scarring upon postmortem examination and
this improvement was higher in SPIO-labeled MSCs com-
pared to nonlabeled MSCs.
To assess cell survival after transplantation in a rat model
of TBI, NSCs were in vitro exposed to BDNF containing
media to induce D
2
R expression [70]. After transplantation
of D
2
R expressing NSC, significant increased binding of
11C-NMSP, a specific tracer of the D
2
R, was observed via
PET (Figure 6). A continuous decrease in tracer uptake
was detected over time; however cell visualization remained
feasible 14 days after transplantation.The therapeutic effect of
the NSCs was assessed via 18F-FDG and showed significant
metabolic recovery in cell-treated animals. Also neurological
motor function was significantly improved.
One clinical studywith SPIO-labeledNSCwas performed
in a TBI patient. Autologous NSCs were labeled with SPIOs
(Feridex®) the day before transplantation and stereotacti-
cally implanted around the brain lesion [179]. Pronounced
hypointense signal was observed at the injection site which
was not present before injection. Clear migration of the
signal could be observed around the lesion suggesting NSC
migration from the injection site towards the border of the
damaged tissue. No hypointense signal was observed after 7
weeks, whichmight be attributed to a dilution of the signal by
cell proliferation or loss in cell survival. To demonstrate that
the hypointense signal was not generated by invading
macrophages, the experiment was repeated in a rat model
of TBI. Histology confirmed the absence of SPIO uptake by
macrophages [179].
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Figure 6: Typical examples of 11C-NMSPmicro-PET imaging in various conditions. Coronal and axial sections of rat brain are shown.White
cross markers in the coronal and axial sections indicate the same position in a scan. (a) Typical image of 11C-NMSP micro-PET in normal
rat brain showing high 11C-NMSP accumulation in striatum. (b) L/N ratio of 11C-NMSP decreased after traumatic brain injury. (c) High
accumulation of 11C-NMSP indicated the existence of transplanted DRD2-positive NSCs [70].
5.6. Spinal Cord Injury. To assess the best administration
route for MSCs in rats with SCI, cells were labeled with
111In-oxine and administered either intravenously or in the
lesion site [180]. The direct injection at the lesion site was
clearly superior compared to the intravenous injection since
all activity was retrieved in the area of the lesion without any
migration towards the other organs throughout the study. In
contrast, the intravenous administration resulted in distribu-
tion of the cells towards the spleen, liver, and kidneys with
hardly any activity in the vertebral column and no activity in
the spinal cord. Another study with SPIO-labeled MSCs was
however capable of detecting the cells with ex vivoMRI in the
lesion site after intravenous injection [181]. Furthermore, they
demonstrated improvement in Basso, Beattie, and Bresnahan
(BBB) locomotor score, heat sensitivity, and lesion size in cell-
treated animals. Injection of SPIOs as such resulted in only
weak hypointense signal in the lesion site, indicatingminimal
uptake of the NP by macrophages which was also confirmed
by histology.
Also the intrathecal administration route was evaluated
for SPIO-labeled MSCs [182]. In this study, they used the
SPIOs not only as contrast agent but also as a method to
magnetically target the labeled cells. Hypointense signal was
higher at the lesion site in themagnetically guided group.The
higher cell migration towards the lesion site was associated
with increased beneficial effects including axonal integrity
and BBB locomotor rating scale. Therefore, magnetic
guidance technology for cell delivery might be a promising
approach for clinical treatment of SCI.
To have an increased understanding on cell survival after
transplantation in mice with SCI Okada et al. transplanted
Fluc expressingNSCs in injured spinal cords either during the
acute phase (immediately after SCI) or 9 days after the injury
(delayed phase) [183]. Drastic reduction in signal intensity
was observed the first 4 days after transplantation, which
was followed by a relatively stable bioluminescent signal for
6 weeks. No difference in cell survival was observed in cells
transplanted during the acute or delayed phase. However, the
faith of the transplanted NSCs was clearly different. During
the acute phase, cells mainly differentiated towards astrocytic
glial scar tissue with only a small percentage differentiating
to neurons and oligodendrocytes. In the delayed phase
however, neuronal and oligodendrocyte markers were clearly
expressed, indicating the importance of the microenviron-
ment on the differentiation of transplanted NSC. In both
conditions partial recovery of hind-limb movement was
observed within 1 week after transplantation followed by
a period of gradual recovery, whereas slower recovery was
observed in sham-treated animals.
All the beneficial preclinical effects of stem cell therapy in
SCI combined with the added value of noninvasive imaging
resulted in two case reports where SPIO-labeled cells were
monitoredwith a clinical imaging system after transfer in SCI
patients [117, 184]. Callera and de Melo performed a prelim-
inary safety study to evaluate the possibility to deliver bone
marrow precursor cells (CD34+ cells) into the spinal cord
via an intrathecal transplantation approach in patients with
SCI [117]. Twenty days after transplantation, a hypointense
signal was specifically visible at the lesion site in 50% of the
cell-treated patients (𝑛 = 10) and the signal persisted until
the end of the MRI follow-up period (35 days) (Figure 7).
Cell monitoring was feasible if the injected cell number was
higher than 0.7 × 106 cells. In the 24-week follow-up period,
no adverse events were observed. Chotivichit et al. treated a
single SCI patient with SPIO-labeled MSCs [184]. The same
injection route was used as in the previous study; however
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(a) (b) (c)
Figure 7: Examples of sagittal resonance images of the spinal cord at the site of the injury, T4-T5 level (white circle) obtained from patient
5 before (a) and 20 and 35 days after labeled-CD34+ cells transplantation ((b) and (c), resp.). The suggested CD34 cell migration into the
injured site is demonstrated as hypointense areas (black areas) in (b) and (c) (arrows). These hypointense areas are not seen in (a) (arrows)
[117].
a significantly higher amount of cells (30 × 106 cells) was
injected. To achieve this cell quantity cells were maintained
in primary culture for four weeks. Immediately after infusion
an MRI scan was performed to validate cell injection in the
arachnoid space and a hypointense signal was observed in the
subarachnoid space and some in the cauda equina but not in
the cervical spine cord. Two days later a hypointense signal
was observed at the injured cervical spine.The signal was very
faint two weeks after transplantation and was not detectable
at two and seven months after transplantation. There was no
change in spinal cord structure based on MRI. Furthermore,
no improvement in neurological deficit was observed with
evenworsening of neuropathic pain in the patient. Additional
adverse events were headache, fever, and transient neurolog-
ical deficit. These problems were also reported in other stud-
ies involving intrathecal stem cell transplantation, with or
without stem cell labeling [185, 186].
5.7. Skeletal Muscle Injury. To assess the impact of MSCs on
skeletal muscle injury cells were labeled with SPIOs. One
week after inducing muscle trauma, animals were trans-
planted with 2.5 × 106 or 5.0 × 106 SPIO-labeled MSC at the
lesion site [187]. One day after transplantation, hypointense
areas appearedwithin the traumatized soleusmuscle and they
remained detectable throughout the investigation period of
65 weeks. No difference in gray scale values was observed
between the animals transplanted with 2.5 × 106 or 5.0 × 106
cells. The absence of migration as determined with MRI sup-
ports the theory of cytokine release which improves muscle
healing. AnMRI-based imaging approach was howevermore
complicated because of the hypointense signals observed in
normal tissue, such as blood vessels, tendons, and boundary
layers between the muscles.
Another study used a BLI-based approach with MSCs
isolated from ubiquitously Fluc expressing transgenic rats
[188, 189]. Cells were also magnetically labeled to allow
guidance towards the injured sites. After transplantation BLI
signal could be observed in both themagnetically guided and
nonguided group and gradually decreased after day 3 until it
was hardly detectable in vivo after 4weeks. Cell survival in the
magnetically guidedMSCswas higher until 3 days after injec-
tion. Although no differences could be observed at later time
points via in vivoBLI, ex vivoBLI showeddetectable cell grafts
in themuscles 4 weeks after injection and the highest BLI sig-
nal was present in the magnetically guided group. Functional
recovery, improved revascularization, and reduced fibrosis
were observed in all cell-treated animals and these effects
were significantly higher in the magnetically guided group.
Since SCs are the endogenousmachinery to repairmuscle
fibers, also SCs were evaluated for their effect in skeletal mus-
cle injuries. Therefore, SCs have been isolated from ubiqui-
tously Fluc expressing transgenicmice. Either freshly isolated
SCs or cultured primary myoblasts were injected intramus-
cularly in nonobese diabetic/severely combined immune-
deficient (NOD/SCID) mice depleted of endogenous SC by
18Gy irradiation [59]. At 4 weeks after injection only freshly
isolated SCs produced a robust BLI signal while the cultured
myoblasts were barely detectable. A dose-response curve
assessed that if high numbers of SCs (500–5000 cells) were
transplantedmore than 80%of themice showed engraftment,
while this was only 16% if only 10 cells were transplanted. BLI
also demonstrated that the cells proliferated after injection
until reaching a plateau in which tissue homeostasis was
obtained. Furthermore, transplanted SCs have shown to
specifically proliferate in response to injury as demonstrated
via ∼80-fold increase in BLI signal. To establish if SCs also
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migrate towards an injury site after systemic injection, SCs
were labeled with 111In-oxine [190]. First, cells were injected
into uninjured rat tibialis anteriormuscle and the distribution
of 111In-labeled cells was clearly visible on SPECT from 2
to 168 h after injection. There was a continuous decrease in
decay-corrected radioactivity at the transplanted site indi-
cating diminishing cell numbers, which is in accordance
with low survival rates of SCs after intramuscular injection
[191]. Afterwards, labeled SCs were injected intravenous in
an acute muscle injury model and healthy animals. Three
hours after transplantation, barely any activity was detectable
in both injured and healthy muscles. Starting from 24 h after
transplantation, 111In-labeled cells could be retrieved in the
injured leg and from 78 h until 168 h after transplantation
this was significantly higher compared to healthy muscles.
The therapeutic effect of the SCs was however insufficient to
maintain muscle mass.
6. Conclusion
Stem cells have shown great potential in several neurodegen-
erative and neuromuscular disorders in preclinical research.
Unfortunately, stem cells have not yet achieved their true
potential in humans with clinical efficacy being very low or
absent in all clinical studies. The number of treated patients
however was too small to evaluatemodest therapeutic benefit
but everyone feels that there is a need for improving stem cell
mediated therapy in humans. To optimize stem cell therapy,
we have to understand how the cells are behaving in vivo and
this is where imaging is of crucial importance. It allows longi-
tudinally and noninvasively following the distribution of the
cells in vivo.
Different cell imaging methods have been developed
that even allow cell visualization on clinically used imaging
devices such as PET, SPECT, and MRI. MRI provides good
anatomical information but has reduced sensitivity and is
mainly associated with a disconnection of the signal from its
target when the labeled cells die. This results in uncertainty
when interpreting the images and makes it difficult to make
strong conclusions. PET and SPECT have a relatively lower
spatial resolution but are highly sensitive and are read-
ily quantifiable. Furthermore, several (human) radionuclide
reporter genes have been developed. The use of reporter
genes allows directly visualizing cell survival, amount, and
proliferation, three factors which are crucial in evaluating the
regenerative potential of stem cells. Also for the development
of induced pluripotent stem cell- (iPSC-) derived therapies
indirect labeling can be of great use as a safety measure
to observe teratoma formation noninvasively. Furthermore,
reporter genes can be placed under control of a tissue specific
promoter to noninvasively monitor stem cell differentiation
and functionality in vivo.
The major drawback of reporter gene-based imaging is
the incorporation of genomic material in the cell. How-
ever, with the recent developments of site-specific genome-
editing approaches, such as zinc-finger nucleases, transcrip-
tion activator-like effector nucleases, and clustered regu-
larly interspaced short palindromic repeats/caspase 9, safe
incorporation of the reporter gene in dedicated areas of the
genome becomes feasible which opens the doors for reporter
gene-based imaging in a clinical setting [192]. Only by further
exploring the possibilities of stem cell monitoring will we be
able to evaluate and decipher the mode of action of stem cell
therapy in different diseases.
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